Abstract

Owing to a highly variable natural course, the benefits of a successful treatment may be marginal for many hepatitis C patients. Therefore, the ability to discriminate patients with chronic hepatitis C virus (HCV) infection at risk of severe consequences, to whom more aggressive treatment strategies should be directed, would be important for clinicians. To review the status of medical research in this area and its transferability to today's medical diagnostics. A Medline search was conducted with the keywords hepatitis C, fibrosis, cirrhosis, polymorphism(s) and outcome. Other papers were identified from personal knowledge by the authors or reviewing the references of articles otherwise selected. The vast majority of data were generated by a candidate-gene strategy, ending in conflicting or irreproducible results. Lack of consistent associations between specific single nucleotide polymorphisms and fibrosis severity in hepatitis C has many reasons, including small sample size, mixed ethnicity of the populations studied, and heterogeneity of outcome measures. Recently, assaying tens of thousands of single nucleotide polymorphisms in a multistage research strategy and using a combination of several different single nucleotide polymorphisms have set the stage for future, high-quality studies. This will hopefully close the gap between research and clinical applications in this area.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.